Lifesci Capital Predicts MBX Biosciences Q1 Earnings

MBX Biosciences, Inc. (NASDAQ:MBX) – Equities researchers at Lifesci Capital issued their Q1 2026 EPS estimates for shares of MBX Biosciences in a research report issued on Tuesday, March 31st. Lifesci Capital analyst P. Dolezal expects that the company will post earnings of ($0.66) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. Lifesci Capital also issued estimates for MBX Biosciences’ Q2 2026 earnings at ($0.67) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.69) EPS.

MBX Biosciences (NASDAQ:MBX) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.15.

Other equities research analysts have also issued research reports about the company. Truist Financial set a $50.00 price target on MBX Biosciences in a research report on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of MBX Biosciences in a research note on Thursday, March 12th. Guggenheim raised their target price on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a research note on Thursday, January 22nd. Finally, Barclays initiated coverage on shares of MBX Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.56.

MBX Biosciences Stock Performance

NASDAQ:MBX opened at $32.99 on Friday. MBX Biosciences has a 1 year low of $4.81 and a 1 year high of $44.89. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -13.69 and a beta of 1.25. The stock has a 50-day moving average price of $33.31 and a two-hundred day moving average price of $28.27.

Insider Activity

In other news, CEO P. Kent Hawryluk bought 18,500 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average price of $28.41 per share, with a total value of $525,585.00. Following the transaction, the chief executive officer owned 486,777 shares in the company, valued at $13,829,334.57. This represents a 3.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 52.19% of the company’s stock.

Institutional Trading of MBX Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP lifted its position in shares of MBX Biosciences by 112.8% in the third quarter. Wellington Management Group LLP now owns 4,823,336 shares of the company’s stock worth $84,408,000 after purchasing an additional 2,556,708 shares in the last quarter. Braidwell LP bought a new position in MBX Biosciences in the fourth quarter valued at $32,127,000. Deep Track Capital LP increased its stake in MBX Biosciences by 43.9% in the 3rd quarter. Deep Track Capital LP now owns 3,150,000 shares of the company’s stock valued at $55,125,000 after buying an additional 961,408 shares during the last quarter. Eventide Asset Management LLC acquired a new stake in MBX Biosciences in the 4th quarter valued at $28,071,000. Finally, Franklin Resources Inc. lifted its position in MBX Biosciences by 164.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,307,288 shares of the company’s stock worth $22,878,000 after buying an additional 812,436 shares in the last quarter.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.